Hologic, Inc. $HOLX Shares Acquired by GAMMA Investing LLC

Key Points

• GAMMA Investing LLC increased its stake in Hologic, Inc. by 129.4% in Q2, owning 7,269 shares worth approximately $474,000.
• CEO Stephen P. Macmillan sold 138,358 shares of Hologic, reducing his ownership by 10.08% and retaining shares valued at around $82.7 million.
• Hologic's Q2 earnings exceeded expectations, reporting $1.08 EPS with a revenue of $1.02 billion, while several analysts have upgraded their price targets for the stock.

GAMMA Investing LLC grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 129.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,269 shares of the medical equipment provider's stock after purchasing an additional 4,100 shares during the period. GAMMA Investing LLC's holdings in Hologic were worth $474,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of HOLX. Victory Capital Management Inc. increased its holdings in shares of Hologic by 34.4% in the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after purchasing an additional 1,692,177 shares during the period. Nuance Investments LLC increased its holdings in shares of Hologic by 623.7% in the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock valued at $66,794,000 after purchasing an additional 931,920 shares during the period. Redwood Wealth Management Group LLC acquired a new position in shares of Hologic in the first quarter valued at about $3,534,000. Invesco Ltd. grew its holdings in Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after acquiring an additional 764,573 shares during the period. Finally, Nuveen LLC acquired a new stake in Hologic during the first quarter worth about $30,317,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.88% of the company's stock.

Hologic Stock Performance

NASDAQ HOLX opened at $65.79 on Friday. The company has a market cap of $14.63 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 2.41 and a beta of 0.57. The stock's 50 day simple moving average is $66.70 and its 200-day simple moving average is $62.83. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on HOLX shares. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their target price for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Morgan Stanley raised their target price on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a report on Thursday, July 31st. UBS Group raised their target price on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Argus raised their target price on Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Finally, Stephens reiterated an "overweight" rating and set a $78.00 price target on shares of Hologic in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $79.38.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.